Tandem Diabetes Care (NASDAQ:TNDM) Issues Quarterly Earnings Results

Tandem Diabetes Care (NASDAQ:TNDM) issued its quarterly earnings results on Thursday. The medical device company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.16, FiscalAI reports. The company had revenue of $247.22 million for the quarter, compared to the consensus estimate of $240.41 million. Tandem Diabetes Care had a negative return on equity of 68.23% and a negative net margin of 20.17%.The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.66) EPS.

Here are the key takeaways from Tandem Diabetes Care’s conference call:

• Tandem reported strong Q1 results with more than 29,000 pump shipments and $247 million in sales, and management is reaffirming 2026 guidance.
• The company has begun its PayGo pharmacy rollout, achieving ~40% formulary coverage early and <5% initial pharmacy ordering, a strategic shift management says will raise ASPs and margins as execution scales.
• Product momentum accelerated: Mobi now supports Android in the U.S., Control‑IQ+ cleared for use in pregnancy (first AID cleared for pregnancy in the U.S.), Libre 3 Plus and Dexcom G7 integrations planned, international Mobi launch in Q2, and a Mobi Tubeless 510(k) filing and a pivotal fully closed‑loop study are on track.
• Infusion set supplier shortages created modest supply‑sales pressure and meaningful customer impact for affected SKUs, with the company expecting disruption to persist into Q2 and some $3M–$4M timing headwinds from the international go‑direct transition.
• Margins and balance sheet strengthened: Q1 non‑GAAP gross margin was 55% (a Q1 record), adjusted EBITDA improved, the company generated $5M free cash flow and ended the quarter with $570M in cash (including $276M net proceeds from convertible debt), supporting execution of strategy.

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock traded up $0.44 on Thursday, reaching $18.47. The company’s stock had a trading volume of 2,622,228 shares, compared to its average volume of 1,653,314. The company has a debt-to-equity ratio of 2.00, a quick ratio of 2.02 and a current ratio of 2.55. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -6.02 and a beta of 1.64. The business’s fifty day moving average price is $21.32 and its 200 day moving average price is $20.33. Tandem Diabetes Care has a twelve month low of $9.98 and a twelve month high of $29.65.

Hedge Funds Weigh In On Tandem Diabetes Care

Institutional investors and hedge funds have recently bought and sold shares of the business. Fox Run Management L.L.C. bought a new stake in Tandem Diabetes Care in the fourth quarter valued at about $251,000. Mercer Global Advisors Inc. ADV bought a new stake in Tandem Diabetes Care in the fourth quarter valued at about $248,000. Arrowstreet Capital Limited Partnership bought a new stake in Tandem Diabetes Care in the second quarter valued at about $231,000. Prelude Capital Management LLC bought a new stake in Tandem Diabetes Care in the third quarter valued at about $228,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Tandem Diabetes Care in the first quarter valued at about $225,000.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TNDM. Bank of America upgraded Tandem Diabetes Care from an “underperform” rating to a “neutral” rating and boosted their price objective for the company from $15.00 to $30.00 in a research report on Friday, February 20th. Stifel Nicolaus boosted their price objective on Tandem Diabetes Care from $20.00 to $22.00 and gave the company a “hold” rating in a research report on Friday, February 20th. The Goldman Sachs Group decreased their price target on Tandem Diabetes Care from $28.00 to $25.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Lake Street Capital raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $50.00 price target on the stock in a research note on Monday, February 23rd. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $25.00 price target (up from $18.00) on shares of Tandem Diabetes Care in a research note on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.05.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.